Navigation Links
LMS integrated obstetrics solution achieves general availability
Date:9/24/2007

MONTREAL, Sept. 24 /PRNewswire-FirstCall/ - LMS Medical Systems (AMEX:LMZ; TSX:LMZ), a healthcare technology company and developer of the CALM(R) clinical information system and risk management software for obstetrics, today announced that Horizon Perinatal Care(TM), the first obstetrics (OB)/perinatal information system designed to support continuity of care between the labor and delivery (L&D) department and other hospital departments and units, developed in conjunction with McKesson Provider Technologies, has become generally available in the marketplace.

Horizon Perinatal Care seamlessly integrates with McKesson's enterprise clinical systems to provide ready access to historical patient information and eliminate redundant charting in support of providing safer, more efficient care to baby and mother. The integrated solution combines fetal strip archival and surveillance capabilities with McKesson's Horizon Clinicals(R) suite of solutions that are used in obstetrical care such as enterprise clinical history and interventions, documentation and bar-code medication administration.

"This milestone is the result of a joint development effort on the part of many dedicated people at both companies," said Diane Cote, President and CEO of LMS. "Bringing the product to life with LMS obstetrical solutions will mean safer deliveries for expectant mothers while providing clinicians a simpler, much needed system within which to work."

About LMS: LMS is a leader in the application of advanced mathematical modeling and neural networks for medical use. The LMS CALM Suite provides physicians, nursing staff, risk managers and hospital administrators with OB clinical information systems and risk management tools designed to improve outcomes and patient care for mothers and their infants during childbirth.

Horizon Perinatal Care is a trademark of McKesson.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed implied by the forward-looking statements including, but without limitation, economic conditions in general and in the healthcare market, the demand for and market for our products in domestic and international markets, our current dependence on the CALM product suite, the challenges associated with developing new products and obtaining regulatory approvals if necessary, research and development activities, the uncertainty of acceptance of our products by the medical community, the lengthy sales cycle for our products, third party reimbursement, competition in our markets, including the potential introduction of competitive products by others, our dependence on our distributors, physician training, enforceability and the costs of enforcement of our patents, potential infringements of our patents and the other factors set forth from time to time in the Company's filings with the United States Securities and Exchange Commission and with the Canadian Securities Commissions. The Company has no intention of or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE LMS MEDICAL SYSTEMS INC.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Integrated Disease Surveillance Project Soon In The Country
2. Integrated Child Development Scheme
3. Mumbai to Have Integrated Trauma Care Facility
4. Latest IPCC Report Highlights Need for Integrated Climate/human Behavior Models
5. Integrated Trauma Care Facility in Mumbai
6. Negligence Cases in the Obstetrics Department Increases Fatality Rates
7. Malpractice Worry Discouraging Medical Students From Taking Up Obstetrics And Gynecology
8. Half a Million Dollars Offered for GPs With Expertise in Anesthetics and Obstetrics
9. TIZANIDINE - New solution to chronic headache
10. A Solution To Quit Smoking Without Gaining Weight
11. Radiation Therapy An Effective Solution For Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: